# Canakinumab With Darbepoetin Alfa in PTs With Lower-Risk MDS Who Have Failed ESA

> **NCT04798339** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **H. Lee Moffitt Cancer Center and Research Institute** · enrollment: 13 (actual)

## Conditions studied

- Myelodysplastic Syndromes

## Interventions

- **DRUG:** Canakinumab Injection
- **DRUG:** Darbepoetin Alfa

## Key facts

- **NCT ID:** NCT04798339
- **Lead sponsor:** H. Lee Moffitt Cancer Center and Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-03-30
- **Primary completion:** 2025-05-26
- **Final completion:** 2026-07
- **Target enrollment:** 13 (ACTUAL)
- **Last updated:** 2025-10-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04798339

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04798339, "Canakinumab With Darbepoetin Alfa in PTs With Lower-Risk MDS Who Have Failed ESA". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04798339. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*